Importantly, ALS-MDMi recapitulated ALS neuropathology hallmarks, i.e., abnormal phosphorylated and non-phosphorylated TDP-43 cytoplasmic accumulation and phagocytosis impairment that paralleled ALS progression; altered neuroinflammatory cytology; DNA damage; NLRP3 inflammasome’s activation; and microglia pyroptosis. The gene discussed is NLRP3; the disease is amyotrophic lateral sclerosis.